Australian Government

Department of Health, Disability and Ageing

Therapeutic Goods Administration

Public Case Details

Filter(s):

TGA ICSR Identifier:
455264,456922,464734,789008,818489,823994,827977,830789,837386,844501,845447,845458,850787,859521,864262,867730,867828.

Number of cases in this report: 17.

18 May 2026

Limitations of the data

This document contains information from reports of adverse events that the TGA has received in relation to therapeutic goods. It does not contain all known information, and an assessment of the safety of a medicine cannot be made based on this information.

Causality

- The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. The reporter may be a health professional, a sponsor, or a member of the public.
- Adverse events are suspected of being related to a therapeutic good, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors.
- There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case ID: AU-TGA-0000455264

Case Details
Report Date: 18/01/2019
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:
Sex: Male
Age:
State: Unknown

Sender Details:
Sender type: Other (e.g. distributor or other organisation)

Reporter Details:
Qualification: Consumer or other non health professional

Case narrative:
s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Hypersensitivity				s11C(1)(a)

Drug information:

(1) SARM S22 FORTE - NOT ON THE ARTG (Enobosarm - SARM S-22 Forte) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(2) ULTIMATE REBUILDER BUNDLE (BPC-157; Ipamorelin; TB-500; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	

Action Taken:	

Case ID: AU-TGA-0000456922

Case Details

Report Date: 12/02/2019
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a) [redacted]

Patient Details:

Sex: Female
Age: 16
State: Unknown

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F [redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Abdominal pain				s11C(1)(a) [redacted]
Anxiety				
Blood pressure increased				
Heart rate increased				
Hypokalaemia				
Nausea				
Neutrophil count increased				
Palpitations				
Tremor				
Vomiting				
White blood cell count increased				

Drug information:

(1) MELANOTAN 2 (Melanotan II; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000464734

Case Details
Report Date: 09/05/2019
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:
Sex: Another term
Age:
State: Unknown

Sender Details:
Sender type: Patient/Consumer

Reporter Details:
Qualification:

Case narrative:
s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Abdominal distension	s47F			s11C(1)(a)
Asthenia				
Fatigue				
Mood altered				
Muscle atrophy				

Drug information:

(1) PEPTILAB CJC-1295 (growth hormone-releasing factor; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(2) TRADENAME NOT SPECIFIED (GHRP-6) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000789008

Case Details

Report Date: 18/10/2023
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 38
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification: Pharmacist

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Paraesthesia	s47F		s11C(1)(a)	s11C(1)(a)
Peripheral swelling	s47F		s11C(1)(a)	s11C(1)(a)
Rash erythematous	s47F		s11C(1)(a)	s11C(1)(a)

Rash maculo-papular	s47F		s11C(1)(a)	s11C(1)(a)
Taste disorder	s47F		s11C(1)(a)	s11C(1)(a)
Urticaria	s47F		s11C(1)(a)	s11C(1)(a)

Drug information:

(1) ULTIMATE REBUILDER BUNDLE (BPC-157; Ipamorelin; TB-500; Unapproved peptide product) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	

(2) ONDANSETRON (ondansetron) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(3) ZYRTEC (cetirizine hydrochloride) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000818489

Case Details

Report Date: 22/08/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 33
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Anaphylactic reaction	s47F	s47F	s11C(1)(a)	s11C(1)(a)

Drug information:

(1) PEPTILAB CJC-1295 (growth hormone-releasing factor; Unapproved peptide product) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	

Case ID: AU-TGA-0000823994

Case Details

Report Date: 03/11/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 38
State: s47F

Sender Details:

Sender type: Patient/Consumer

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Plantar fasciitis	s47F		s11C(1)(a)	
Product packaging issue				s11C(1)(a)
Tendonitis	s47F		s11C(1)(a)	

Drug information:

(1) BPC-157 (BPC-157; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000827977

Case Details

Report Date: 17/12/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 35
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification: Pharmacist

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Serum sickness				s11C(1)(a)
Systemic inflammatory response syndrome			s11C(1)(a)	s11C(1)(a)

Drug information:

(1) BPC-157 (BPC-157; Unapproved peptide product) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F, Stopped: s47F
Indication:	
Action Taken:	

Case ID: AU-TGA-0000830789

Case Details
Report Date: 03/02/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:
Sex: Male
Age: 39
State: s47F

Sender Details:
Sender type: Health Professional

Reporter Details:
Qualification:

Case narrative:
s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Arthralgia	s47F	s47F		s11C(1)(a)
Influenza like illness				
Insomnia				
Lethargy				
Sensitive skin				
Vision blurred				

Drug information:

(1) TB-500 - COMPOUNDED PRODUCT (TB-500; Unapproved peptide product) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(2) ASPIRIN (aspirin) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(3) PREDNISONE (prednisone) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(4) PROPRANOLOL HYDROCHLORIDE (propranolol hydrochloride) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000837386

Case Details

Report Date: 17/04/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 51
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Renal artery thrombosis			s11C(1)(a)	s11C(1)(a)

Drug information:

(1) MELANOTAN 2 (Melanotan II; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

(2) TESTOSTERONE (testosterone) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000844501

Case Details

Report Date: 07/07/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 43
State: s47F

Sender Details:

Sender type: Patient/Consumer

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Hypersensitivity	s47F	s47F		s11C(1)(a)
Pain	s47F			
Palpitations	s47F			
Pruritus	s47F			

Drug information:

(1) TRADENAME NOT SPECIFIED (Ipamorelin) - Suspect	
Dosage information:	

Treatment details:	
Indication:	
Action Taken:	

(2) PEPTILAB CJC-1295 NO DAC (growth hormone-releasing factor; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000845447

Case Details

Report Date: 17/07/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Another term
Age:
State: Unknown

Sender Details:

Sender type: Regulatory Authority

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Third degree chemical burn of skin				s11C(1)(a)

Drug information:

(1) PHATT TAN MELO INFUSED OIL (Melanotan II; Unapproved peptide product; Undisclosed Ingredients) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000845458

Case Details

Report Date: 17/07/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Another term
Age:
State: Unknown

Sender Details:

Sender type: Regulatory Authority

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Malaise				s11C(1)(a)

Drug information:

(1) PHATT TAN MELANOTAN II NASAL SPRAY (Melanotan II; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(2) PHATT TAN SEMAGLUTIDE (Semaglutide) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000850787

Case Details

Report Date: 17/09/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 51
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Other health professional

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Renal artery thrombosis				s11C(1)(a)

Drug information:

(1) MELANOTAN 2 (Melanotan II; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TESTOSTERONE (testosterone) - Suspect

Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000859521

Case Details

Report Date: 10/12/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 33
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Cold sweat	s47F			s11C(1)(a)
Headache				
Hot flush				
Injection site reaction				
Pruritus	s47F			

Rash	s47F				s11C(1)(a)	

Drug information:

(1) PEPTILAB CJC-1295 (growth hormone-releasing factor; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

Case ID: AU-TGA-0000864262

Case Details

Report Date: 24/02/2026
Modified on: 26/02/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 51
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Consumer or other non health professional

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Renal artery thrombosis				s11C(1)(a)

Drug information:

(1) MELANOTAN 2 (Melanotan II; Unapproved peptide product) - Suspect	
Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TESTOSTERONE (testosterone) - Suspect	
Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000867730

Case Details

Report Date: 10/04/2026
Modified on: 17/05/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 58
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Affect lability	s47F	s47F	s11C(1)(a)	s11C(1)(a)
Suicidal ideation	s47F	s47F		s11C(1)(a)

Drug information:

(1) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

Case ID: AU-TGA-0000867828

Case Details

Report Date: 13/04/2026
Modified on: 17/05/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Not Specified
Age:
State: s47F

Sender Details:

Sender type: Health Professional

Reporter Details:

Qualification:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Adverse reaction				s11C(1)(a)

Drug information:

(1) EVERLAB - RETATRUTIDE (Retatrutide; Unapproved peptide product) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	
Action Taken:	

Public Case Details

Filter(s):

Report Date: >=01/01/2024<=27/04/2026

Study Type: Clinical trials,Other studies,Unknown,Individual patient use

Case Decision: Accepted

Characterisation: Suspect,Interacting

Generic Name: BPC-157 ; Unapproved peptide product,Melanotan II ; Unapproved peptide product,Melanotan II ; Unapproved peptide product ; Undisclosed Ingredients,Retatrutide,Retatrutide ; Unapproved peptide product,TB-500 ; Unapproved peptide product.

Number of cases in this report: 28.

Limitations of the data

This document contains information from reports of adverse events that the TGA has received in relation to therapeutic goods. It does not contain all known information, and an assessment of the safety of a medicine cannot be made based on this information.

Causality

- The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. The reporter may be a health professional, a sponsor, or a member of the public.
- Adverse events are suspected of being related to a therapeutic good, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors.
- There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case ID: AU-TGA-0000811269

Case Details

Report Date: 29/05/2024
Modified on:
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 48
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Abdominal pain	s47F	s47F		s11C(1)(a)
Diarrhoea	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) AMLODIPINE (amlodipine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) TRADENAME NOT SPECIFIED (olmesartan medoxomil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	


s47F

Case ID: AU-TGA-0000817624

Case Details

Report Date: 09/08/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 47
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

[redacted]

Reactions:

Preferred te m	Onset date	End date	Management of Event	Outcome
Gastroenteri s	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TRADENAME NOT SPECIFIED (evolocumab) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(3) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) LOPERAMIDE HYDROCHLORIDE (loperamide hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

Case ID: AU-TGA-0000820647

Case Details

Report Date: 18/09/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 78
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F

[redacted]

Reactions:

Preferred term	Onset date	End da e	M nagemen o vent	Outcome
Diverticulitis	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) AMLODIPINE (amlodipine) - Concomitant		
Dosage information:	s11C(1)(a)	
Treatment details:	Started: s47F	Stopped: s47F

Indication:	s11C(1)(a)
Action Taken:	

(3) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) PERINDOPRIL ARGININE (perindopril arginine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) SOMAC (pantoprazole) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F




s47F

Case ID: AU-TGA-0000821498

Case Details

Report Date: 30/09/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 68
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Hypomagnesaemia	s47F	s47F		s11C(1)(a)
Malnutrition	s47F	s47F		

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LOPERAMIDE HYDROCHLORIDE (loperamide hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(3) METFORMIN HYDROCHLORIDE (metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) PANADOL OSTEO (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) PERINDOPRIL (perindopril) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	

(6) PERINDOPRIL (perindopril) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F



s47F




s47F

s47F

Case ID: AU-TGA-0000823672

Case Details

Report Date: 30/10/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 59
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Anaphylactic reaction	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) ATOZET (atorvastatin calcium trihydrate; ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) METFORMIN XR (metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) PARACETAMOL (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(6) PERINDOPRIL (perindopril) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000826035

Case Details

Report Date: 27/11/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 79
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F




s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Cellulitis	s47F	s47F		s11C(1)(a)
Hypotension				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) AMLODIPINE (amlodipine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	St rted: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) BENZATHINE BENZYLPENICILLIN (benzathine benzylpenicillin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) DULOXETINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) DULOXETINE () - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(9) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) LORATADINE (loratadine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) MICARDIS (telmisartan) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	

(12) MICARDIS (telmisartan) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) MIRTAZAPINE (mirtazapine) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(14) MIRTAZAPINE (mirtazapine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) MOVICOL [MACROGOL 4000;POTASSIUM CHLORIDE;SOD () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) NALOXONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) NICOTINAMIDE (nicotinamide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(18) NOVASONE (mometasone furoate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(19) ONDANSETRON (ondansetron) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(20) OVESTIN (estriol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(21) OXYCODONE (oxycodone) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(22) PROMETHAZINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(23) SOLIFENACIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(24) TARGIN (naloxone hydrochloride dihydrate; oxycodone hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(25) THYROXINE (levothyroxine sodium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F

Indication:	s11C(1)(a)
Action Taken:	

(26) TRELEGY () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(27) TRIMETHOPRIM (trimethoprim) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(28) TURMERIC & BLACK PEPPER () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(29) VENTOLIN [SALBUTAMOL] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(30) VITAMIN D [VITAMIN D NOS] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

s47F




s47F

Case ID: AU-TGA-0000827417

Case Details

Report Date: 11/12/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 68
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F




s47F

s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Abnormal loss of weight	s47F			s11C(1)(a)
Major depression				
Periprosthetic fracture				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) COLOXYL WITH SENNA (docusate sodium; sennosides) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(3) PANADOL OSTEO (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

s47F


s47F


s47F

Case ID: AU-TGA-0000827418

Case Details

Report Date: 11/12/2024
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 58
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Urinary tract infection	s47F	s47F		s11C(1)(a)
Vomiting				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	
Treatment details:	
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)

Action Taken:	

(4) ATOZET (atorvastatin calcium trihydrate; ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) LOSARTAN POTASSIUM (losartan potassium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) MACROGOL 3350 () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) NEXIUM [ESOMEPRAZOLE SODIUM] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) POTASSIUM CHLORIDE (potassium chloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) SERTRALINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) SLIPPERY ELM (Ulmus rubra) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) SODIUM BICARBONATE (sodium bicarbonate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) SODIUM CHLORIDE (sodium chloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) TRADENAME NOT SPECIFIED (zolpidem tartrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000829852

Case Details

Report Date: 20/01/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 75
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
General physical health deterioration	s47F			s11C(1)(a)
Mobility decreased				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(3) ENDONE (oxycodone hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F

Indication:	s11C(1)(a)
Action Taken:	

(4) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) HYDROCHLOROTHIAZIDE (hydrochlorothiazide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) IRBESARTAN (irbesartan) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) ISOSORBIDE MONONITRATE (isosorbide mononitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) PANTOPRAZOLE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) PARACETAMOL (paracetamol) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) SPIOLTO () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) VITAMIN D [VITAMIN D NOS] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

s47F

Case ID: AU-TGA-0000831201

Case Details

Report Date: 07/02/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 71
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Orthostatic hypotension	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LACTULOSE (lactulose) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) BISOPROLOL () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(5) CLOPIDOGREL (clopidogrel) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(6) EMPAGLIFLOZIN (empagliflozin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)

Action Taken:	s11C(1)(a)

(7) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(8) FUROSEMIDE (furosemide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(9) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(10) INSULIN GLARGINE (Insulin glargine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(11) ISORDIL (diluted isosorbide dinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(12) METFORMIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(13) PERHEXILINE () - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(14) TRADENAME NOT SPECIFIED (rosuvastatin calcium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(15) VENTOLIN [SALBUTAMOL] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

s47F

Case ID: AU-TGA-0000833954

Case Details

Report Date: 11/03/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 58
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F




s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Cardiac failure acute	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) COPLAVIX (aspirin; clopidogrel hydrogen sulfate) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(3) COPLAVIX (aspirin; clopidogrel hydrogen sulfate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) LIPITOR (atorvastatin calcium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a) [redacted]
Treatment details:	Started: s47F [redacted]
Indication:	s11C(1)(a) [redacted]
Action Taken:	

(7) NICORANDIL (nicorandil) - Concomitant	
Dosage information:	s11C(1)(a) [redacted]
Treatment details:	Started: s47F [redacted]
Indication:	s11C(1)(a) [redacted]
Action Taken:	

s47F [redacted]

Case ID: AU-TGA-0000833955

Case Details

Report Date: 11/03/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 60
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F



s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Cervical vertebral fracture	s47F	s47F		s11C(1)(a)
Dizziness postural	s47F	s47F		s11C(1)(a)
Subcutaneous abscess	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a) [redacted]
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a) [redacted]

(2) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a) [redacted]
Treatment details:	Started: s47F
Indication:	s11C(1)(a) [redacted]
Action Taken:	

(3) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(4) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a) [redacted]

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) COLOXYL WITH SENNA [DOCUSATE SODIUM;SENNOSIDE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) FLUTICASONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) METOCLOPRAMIDE (metoclopramide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	
Treatment details:	
Indication:	
Action Taken:	

(11) PERINDOPRIL (perindopril) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) SALBUTAMOL () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) THIAMINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

s47F



Case ID: AU-TGA-0000837649

Case Details

Report Date: 23/04/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 49
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Urinary tract infection	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TRADENAME NOT SPECIFIED (duloxetine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F

Indication:	s11C(1)(a)
Action Taken:	

(3) ESTRIOL (estriol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) ESTROGEL (estradiol hemihydrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) MICROLUT (levonorgestrel) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) PROGESTERONE (progesterone) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) TRADENAME NOT SPECIFIED (salbutamol sulfate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

Case ID: AU-TGA-0000840648

Case Details

Report Date: 27/05/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 53
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F



s47F



Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Decreased appetite	s47F			s11C(1)(a)
Malnutrition				

Ovarian cyst	s47F	s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(5) CARUSOS CONSTIPATION EZE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F

Indication:	s11C(1)(a)
Action Taken:	

(7) ONDANSETRON (ondansetron) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	

(8) ONDANSETRON (ondansetron) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) THYROXINE (levothyroxine sodium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F


s47F

Case ID: AU-TGA-0000843295

Case Details

Report Date: 23/06/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 71
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F



s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of vent	Outcome
Nausea	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) DOCUSATE;SENNA ALEXANDRINA () - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) ISOSORBIDE MONONITRATE (isosorbide mononitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) EMPAGLIFLOZIN;LINAGLIPTIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) EZETROL (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) FERROUS SULPHATE + FOLIC ACID () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) INDACATEROL MALEATE AND GLYCOPYRRONIUM BROMID () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) MAGNESIUM ASPARTATE (magnesium aspartate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) METFORMIN HYDROCHLORIDE (metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) MOVICOL [MACROGOL 3350;POTASSIUM CHLORIDE;SOD () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) NEBIVOLOL (nebivolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) NICORANDIL (nicorandil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(18) NITROFURANTOIN (nitrofurantoin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(19) COLECALCIFEROL (colecalciferol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(20) PANADOL OSTEO (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(21) PANTOPRAZOLE (pantoprazole sodium sesquihydrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(22) PREGABALIN (pregabalin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(23) TRADENAME NOT SPECIFIED (salbutamol sulfate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(24) TARGIN (naloxone hydrochloride dihydrate; oxycodone hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(25) TELMISARTAN/AMLODIPINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F



s47F

Case ID: AU-TGA-0000846636

Case Details
Report Date: 31/07/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:
Sex: Female
Age: 57
State: Unknown

Sender Details:
Sender type: Pharmaceutical Company

Reporter Details:
Qualification: Physician

Case narrative:
s47F


s47F

s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Gastroenteritis viral	s47F	s47F		s11C(1)(a)
Pulmonary embolism	s47F			s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LEVETIRACETAM (levetiracetam) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(3) MEMANTINE HYDROCHLORIDE (memantine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) ARTIGE (methylphenidate hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) TRADENAME NOT SPECIFIED (citalopram hydrobromide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) DOCUSATE SODIUM (docusate sodium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) DYMISTA (azelastine hydrochloride; fluticasone propionate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) ESTROGEL (estradiol hemihydrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) HAIR SKIN NAILS () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) MAXALT (rizatriptan) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) METOCLOPRAMIDE (metoclopramide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) NALTREXONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) CARBIMAZOLE (carbimazole) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) OLANZAPINE (olanzapine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) PANADOL OSTEO (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) PROGESTERONE (progesterone) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(18) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(19) CURCUMIN (curcumin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(20) TRIMBOW () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(21) VALTREX (valaciclovir hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(22) VENTOLIN [SALBUTAMOL] () - Concomitant

Dosage information:	s11C(1)(a) [redacted]
Treatment details:	Started: s47F [redacted]
Indication:	s11C(1)(a) [redacted]
Action Taken:	

s47F [redacted]

s47F



s47F



s47F




s47F

Case ID: AU-TGA-0000849032

Case Details

Report Date: 27/08/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 72
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F




s47F

s47F



s47F



s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Ketosis	s47F			s11C(1)(a)
Middle ear disorder				
Orthostatic hypotension				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	

Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(6) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) DOCUSATE SODIUM & SENNA () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) ISOSORBIDE MONONITRATE (isosorbide mononitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) EMPAGLIFLOZIN;LINAGLIPTIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) EZETROL (ezetimibe) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) FERROUS SULPHATE & FOLIC ACID () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) INDACATEROL ACETATE, GLYCOPYRRONIUM BROMIDE A () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) MAGNESIUM ASPARTATE (magnesium aspartate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) METFORMIN HYDROCHLORIDE (metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) MOVICOL [MACROGOL 4000;POTASSIUM CHLORIDE;SOD () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(18) NEBIVOLOL (nebivolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(19) NICORANDIL (nicorandil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(20) NITROFURANTOIN (nitrofurantoin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(21) ONDANSETRON (ondansetron) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(22) OSTELIN VIT D + CA () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(23) PANADOL OSTEO (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(24) PANTOPRAZOLE (pantoprazole sodium sesquihydrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(25) PREGABALIN (pregabalin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(26) TRADENAME NOT SPECIFIED (salbutamol sulfate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(27) TARGIN (naloxone hydrochloride dihydrate; oxycodone hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(28) TELMISARTAN AND AMLODIPINE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

s47F




s47F

s47F



s47F



s47F




s47F


s47F


s47F

s47F

Case ID: AU-TGA-0000852138

Case Details

Report Date: 06/10/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 58
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Subcutaneous abscess	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(5) PARACETAMOL (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F



s47F




s47F


s47F

Case ID: AU-TGA-0000853485

Case Details

Report Date: 21/10/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 73
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F



s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Man gement of Event	Outcome
Cholelithias	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	
Indication:	
Action Taken:	s11C(1)(a)

(5) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) TRADENAME NOT SPECIFIED (fexofenadine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) FLUOXETINE HYDROCHLORIDE (fluoxetine hydrochloride) - Concomitant	
Dosage information:	
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F

Indication:	s11C(1)(a)
Action Taken:	

(10) METFORMIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) MULTIVITAMINS [VITAMINS NOS] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) GLYCERYL TRINITRATE (glyceryl trinitrate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) TRADENAME NOT SPECIFIED (rosuvastatin calcium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) THYROXINE (levothyroxine sodium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) VITAMIN B12 [VITAMIN B12 NOS] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) ASCORBIC ACID (ascorbic acid) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) VITAMIN D NOS () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

Test and procedures:

Test name	Test date	Normal range	Test result	Comment
s11C(1)(a)	s47F	3-15	Test Result s11C(1)(a) Unit:umol/liter	
s11C(1)(a)	s47F	0-5	Test Result: s11C(1)(a) Unit:mg/L	
s11C(1)(a)	s47F	10-65	Test Result s11C(1)(a) Unit:U/liter	
R2 to R3 transformation				Test Name: s11C(1)(a) s11C(1)(a) Test Date: s47F Notes: s11C(1)(a) ,Test Name: s11C(1)(a) Test Date: s47F Notes: units not provided,Test Name: s11C(1)(a) Test Date s47F s47F Notes: units not provided

Case ID: AU-TGA-0000853821

Case Details

Report Date: 27/10/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 79
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F



Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Haematuria	s47F			s11C(1)(a)
Proctitis				
Urinary retention				

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)

Action Taken:	s11C(1)(a)

(6) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(7) AMLODIPINE (amlodipine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) DITROPAN (oxybutynin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) DUODART 500/400 (dutasteride; tamsulosin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) EZETIMIBE (ezetimibe) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) TRADENAME NOT SPECIFIED (esomeprazole magnesium trihydrate) - Concomitant	
Dosage information:	
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) RIVAROXABAN (rivaroxaban) - Concomitant

Dosage information:	s11C(1)(a)
Treatment details:	Started:s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started:s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

Case ID: AU-TGA-0000855488

Case Details

Report Date: 12/11/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 61
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Diarrhoea	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect			
Dosage information:	s11C(1)(a)		
Treatment details:	Started: s47F	Stopped: s47F	
Indication:	s11C(1)(a)		
Action Taken:	s11C(1)(a)		

(2) LY3437943 (Retatrutide) - Suspect			
Dosage information:	s11C(1)(a)		
Treatment details:	Started: s47F	Stopped: s47F	
Indication:			
Action Taken:	s11C(1)(a)		

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(6) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(7) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(8) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	

Action Taken:	s11C(1)(a)

(9) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) TRADENAME NOT SPECIFIED (rosuvastatin calcium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000855765

Case Details

Report Date: 17/11/2025
Modified on: 10/02/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 60
State: s47F

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F



s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Peripheral arterial occlusive disease	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F

Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(6) CANDESARTAN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) FISH OIL (natural fish oil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)

Action Taken:	

(8) JARDIANCE (empagliflozin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) LERCANIDIPINE HYDROCHLORIDE (lercanidipine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) MOMETASONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) PSYLLIUM HUSK [PLANTAGO OVATA] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) TRAJENTAMET (linagliptin; metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) ZOFRAN [ONDANSETRON] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000859090

Case Details

Report Date: 04/12/2025
Modified on: 30/01/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 80
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Man gement of Event	Outcome
Hypotension	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(4) FERROUS SULFATE (ferrous sulfate) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(5) FOLIC ACID (folic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) INSULIN GLARGINE (Insulin glargine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) METFORMIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) METOCLOPRAMIDE (metoclopramide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) OXYBUTYNIN HYDROCHLORIDE (oxybutynin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) PAROXETINE (paroxetine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) TELMISARTAN (telmisartan) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F

Case ID: AU-TGA-0000859283

Case Details

Report Date: 08/12/2025
Modified on: 02/02/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 85
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Ou come
Rhabdomyolysis	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect

Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(6) TRADENAME NOT SPECIFIED (Acetylsalicylic acid) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) TRADENAME NOT SPECIFIED (atorvastatin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) BISOPROLOL () - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) CANDESARTAN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) COLCHICINE (colchicine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) DABIGATRAN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) TRADENAME NOT SPECIFIED (dapagliflozin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) GAVISCON [CALCIUM CARBONATE;SODIUM ALGINATE;S () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) SODIUM CHLORIDE (sodium chloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	


s47F

Case ID: AU-TGA-0000862863

Case Details

Report Date: 05/02/2026
Modified on: 08/04/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 81
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F



s47F

[redacted]

Reactions:

Preferred term	Onset dat	End date	M nagement of Event	Outcome
Syncope	s47F	s47F		s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) ALLEGRON (nortriptyline hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)

Action Taken:	

(5) ARAVA (leflunomide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(6) TRADENAME NOT SPECIFIED (buprenorphine) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) CENTRUM MEN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) CHOLECALCIFEROL () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) CLOTRIZONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) TRADENAME NOT SPECIFIED (dapagliflozin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) DONEPEZIL () - Concomitant	
Dosage information:	s11C(1)(a)

Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) EPSOM SALTS [MAGNESIUM SULFATE] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) ESOMEPRAZOLE (esomeprazole) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) FLUDROCORTISONE (fludrocortisone) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) FRUSEMIDE [FUROSEMIDE] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) GAVISCON [CALCIUM CARBONATE;POTASSIUM BICARBO () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(17) GLUCOSAMINE HYDROCHLORIDE (glucosamine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(18) HYDROCORTISONE (hydrocortisone) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(19) MIRABEGRON (mirabegron) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(20) PARACETAMOL (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(21) POLYETHYLENE GLYCOL;PROPYLENE GLYCOL () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(22) PREGABALIN (pregabalin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(23) ROSUVASTATIN () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(24) SALBUTAMOL () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(25) SUVOREXANT (suvorexant) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(26) TIOTROPIUM BROMIDE (tiotropium bromide) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(27) VITAMIN B12 NOS () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000863794

Case Details

Report Date: 18/02/2026
Modified on: 05/05/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 54
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Pulmonary embolism	s47F			s11C(1)(a)

Drug information:

(1) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(5) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F Stopped: s47F

Indication:	
Action Taken:	s11C(1)(a)

(6) ESOMEPRAZOLE (esomeprazole) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) PARACETAMOL (paracetamol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F

Case ID: AU-TGA-0000864911

Case Details

Report Date: 04/03/2026
Modified on: 06/05/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Female
Age: 54
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F


s47F

s47F

[redacted]

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Anaemia	s47F			s11C(1)(a)
Hyponatraemia	s47F	s47F		s11C(1)(a)

Drug information:

(1) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(2) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(3) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	
Action Taken:	s11C(1)(a)

(4) TRADENAME NOT SPECIFIED (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

s47F


s47F

Case ID: AU-TGA-0000866116

Case Details

Report Date: 20/03/2026
Modified on: 15/04/2026
Causality: Causality possible
Serious ICSR: s11C(1)(a)

Patient Details:

Sex: Male
Age: 60
State: Unknown

Sender Details:

Sender type: Pharmaceutical Company

Reporter Details:

Qualification: Physician

Case narrative:

s47F

s47F

Reactions:

Preferred term	Onset date	End date	Management of Event	Outcome
Papillary thyroid cancer	s47F			s11C(1)(a)

Drug information:

(1) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(2) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F , Stopped: s47F
Indication:	
Action Taken:	s11C(1)(a)

(3) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(4) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(5) LY3437943 (Retatrutide) - Suspect	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	s11C(1)(a)

(6) TRADENAME NOT SPECIFIED (candesartan cilexetil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(7) FISH OIL (natural fish oil) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(8) JARDIANCE (empagliflozin) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(9) LERCANIDIPINE HYDROCHLORIDE (lercanidipine hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(10) MAGNESIUM (magnesium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(11) TRADENAME NOT SPECIFIED (Metoprolol) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(12) MOMETASONE () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(13) PSYLLIUM HUSK [PLANTAGO OVATA] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(14) TRADENAME NOT SPECIFIED (rosuvastatin calcium) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(15) TRAJENTAMET (linagliptin; metformin hydrochloride) - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

(16) ZOFRAN [ONDANSETRON HYDROCHLORIDE] () - Concomitant	
Dosage information:	s11C(1)(a)
Treatment details:	Started: s47F
Indication:	s11C(1)(a)
Action Taken:	

s47F


s47F